(Q42247976)

19 October 2017

title

The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases (English)

1 reference

diffuse large B-cell lymphoma

19 October 2017

1 reference

1 reference

J Y Hong

1

1 reference

19 October 2017

M E Hong

2

1 reference

19 October 2017

M K Choi

3

1 reference

19 October 2017

Y S Kim

4

1 reference

19 October 2017

W Chang

5

1 reference

19 October 2017

C H Maeng

6

1 reference

19 October 2017

S Park

7

1 reference

19 October 2017

S J Lee

8

1 reference

19 October 2017

I-G Do

9

1 reference

19 October 2017

J-S Jo

10

1 reference

19 October 2017

S H Jung

11

1 reference

19 October 2017

S J Kim

12

1 reference

19 October 2017

Y H Ko

13

1 reference

19 October 2017

W S Kim

14

1 reference

19 October 2017

publication date

1 January 2014

1 reference

19 October 2017

1 reference

19 October 2017

volume

25

1 reference

19 October 2017

issue

1

1 reference

19 October 2017

page(s)

182-188

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Novel therapeutics for aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT530

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT530

1 reference

19 October 2017

1 reference